Neurokinin A

Neurokinin A (NKA), also known as Substance K or Neurokinin α, is a neuropeptide that belongs to the tachykinin neuropeptide family. It is encoded by the TAC1 gene in humans. Neurokinin A acts primarily as a neurotransmitter and neuromodulator in the central nervous system (CNS) and the peripheral nervous system (PNS). It plays a significant role in the regulation of various physiological processes, including pain perception, vasodilation, bronchoconstriction, and modulation of the endocrine system.

Structure and Synthesis

Neurokinin A is derived from a precursor protein known as preprotachykinin-A (PPT-A), which also gives rise to another important tachykinin, Substance P. The processing of PPT-A involves a series of enzymatic steps that result in the production of Neurokinin A, among other peptides. Neurokinin A is a decapeptide, consisting of ten amino acids.

Receptors

Neurokinin A exerts its effects primarily through the activation of the neurokinin receptors, specifically the NK2 receptor. These receptors are part of the G protein-coupled receptor (GPCR) family, which initiates a cascade of intracellular events upon activation. The NK2 receptor has a high affinity for Neurokinin A and is predominantly found in the smooth muscle of various tissues, including the bronchi, gastrointestinal tract, and blood vessels.

Functions

Neurokinin A is involved in a wide range of physiological and pathological processes:

• Pain Transmission: It facilitates the transmission of pain signals in the central and peripheral nervous system.
• Cardiovascular System: Neurokinin A can induce vasodilation, leading to a decrease in blood pressure.
• Respiratory System: It can cause bronchoconstriction, making it of interest in the study of respiratory conditions such as asthma.
• Gastrointestinal System: Neurokinin A affects gastrointestinal motility and secretion, playing a role in digestive processes.

Clinical Significance

Due to its involvement in pain, inflammation, and various autonomic functions, Neurokinin A and its receptors are potential targets for the development of new therapeutic agents. Drugs that block the action of Neurokinin A (NK2 receptor antagonists) are being explored for the treatment of conditions such as asthma, irritable bowel syndrome (IBS), and certain types of pain.

Research Directions

Research on Neurokinin A continues to explore its role in disease and health, aiming to uncover new therapeutic strategies for tachykinin-related disorders. The development of selective NK2 receptor antagonists is a particularly active area of investigation.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian